ESMO 2021 | KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanoma

Ines Pires da Silva, MD, PhD, Melanoma Institute Australia and The University of Sydney, Sydney, Australia, comments on the results of the Phase III KEYNOTE-716 trial (NCT03553836) evaluating the safety and efficacy of pembrolizumab in patients with high-risk stage II melanoma. Whilst this study showed significantly improved outcomes for this patient population, additional data and a longer follow-up period are required to validate those results. In addition, despite its proven benefits, the approval of this treatment might take a significant amount of time. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.